🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

647 results for “Les” Clear

  1. DEXAMETHASONE, Xtandi - 40 mg soft capsules, PF-06821497, DEXAMETHASONE, PF-06821497, PREDNISOLONE, DOCETAXEL

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  2. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  3. DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  4. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  5. Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  6. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  7. Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  8. Diacomit 250 mg hard capsules, Matched Placebo will consist in caspules similar to the 250 and 500 mg capsules of stiripentol but with no active ingredient, Diacomit 500 mg hard capsules

    Biocodex

    Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)

    phase 3 small molecule active

    1 trial

  9. Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets

    Mundipharma Pty Limited

    Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

    phase 3 small molecule active

    1 trial

  10. Dipyridamole 50mg tid

    The First People's Hospital of Lianyungang

    Restless Leg Syndrome Due to Uraemia

    phase 3 small molecule active

    1 trial

  11. Dovato 50 mg/300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Combivir 150 mg/300 mg film-coated tablets, Epivir 300 mg film-coated tablets, Ziagen 300 mg film-coated tablets, Retrovir 250 mg capsules, hard, Kivexa 600 mg/300 mg film-coated tablets, Triumeq 50 mg/600 mg/300 mg film-coated tablets

    Fondazione Telethon ETS

    HIV-infected

    phase 3 small molecule active

    1 trial

  12. Dronabinol Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial

  13. Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment

    United Therapeutics Europe Ltd

    COVID19

    phase 3 small molecule active

    1 trial

  14. Drug use prevention intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Behavior

    phase 3 other completed

    1 trial

  15. EMB-Fatol® 100 mg, Tabletten, The placebo for Amikacin Liposome for Inhalation Suspension drug product is a white translucent suspension consisting of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, which are dispersed in 1.5% (w/w) sodium chloride solution. The placebo is filled into the same container closure system of the drug product, Azithromycin-ratiopharm 250mg Filmtabletten, Azithromycin STADA® 250 mg Filmtabletten, Azithromycin AL 250 mg Filmtabletten, Azitromicina Teva 250 mg comprimidos re

    Insmed Limited

    "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

    phase 3 small molecule active

    1 trial

  16. ETC-1002

    Esperion Therapeutics

    Hypercholesterolemia

    phase 3 small molecule completed

    6 trials

  17. ETIDRONATE DISODIUM ORAL CAPSULES 400 MG

    Disc Medicine

    Pseudoxanthoma Elasticum

    phase 3 small molecule active

    1 trial

  18. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  19. Epcoritamab (GEN3013), Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Epcoritamab (GEN3013), Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  20. Eslicarbazepine acetate (BIA 2-093)

    Bial Portela & Companhia S.A.

    Partial Epilepsy in Children and Adolescents

    phase 3 small molecule completed

    1 trial

  21. Esomeprazole Magnesium, NEXIUM 10 mg gastro-resistant granules for oral suspension, sachet, Esomeprazole Magnesium

    AstraZeneca AB

    Erosive Esophagitis

    phase 3 small molecule active

    1 trial

  22. Etripamil

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia

    phase 3 small molecule terminated

    1 trial

  23. Etripamil NS

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia

    phase 3 small molecule active

    2 trials

  24. Etripamil NS 70 mg

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources